Research · Peptide synopsis

Selank and Semax — research-grade Russian nootropic peptides in the UAE

Wellness Labs Editorial·26 May 2026·9 min read

Selank and Semax come from the same Moscow research program, share the same C-terminal stabilising motif, and address complementary research domains — anxiolytic and immune-modulatory pharmacology for Selank, neuroprotective and cognitive-research pharmacology for Semax. They are routinely discussed as a pair in Russian-language literature and almost never together in English-language summaries. This article corrects that.

The shared lineage

Selank and Semax were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow under a research program that began in the late 1970s and accelerated through the 1980s and 1990s. The shared design strategy is what makes them a natural pair. Each peptide takes a biologically active short sequence from a known endogenous molecule (tuftsin for Selank, ACTH(4-10) for Semax) and stabilises it by appending a Pro-Gly-Pro C-terminus. The terminal Pro-Gly-Pro confers resistance to plasma and brain peptidases — without it, the parent peptides would be degraded within minutes of administration.

The result in both cases is a 7-residue synthetic peptide that retains the receptor-level activity of the parent fragment while extending the in-vivo half-life to a window long enough for intranasal or parenteral dosing to produce measurable pharmacology. Intranasal administration is the route most commonly studied in the Russian clinical work for both compounds — the olfactory pathway gives direct access to central nervous system targets without first-pass metabolism.

Selank — the Tuftsin analogue

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight approximately 751 Da) is a stabilised analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) released from the heavy chain of immunoglobulin G during phagocyte processing. Tuftsin itself is a known immunomodulator; the Selank construction preserves the tuftsin sequence and adds the Pro-Gly-Pro stabilising tail.

The mechanism literature on Selank spans three pathways:

GABAergic modulation. Animal and electrophysiological studies have reported that Selank potentiates GABAergic neurotransmission, with effects on anxiety-related behaviour in rodent models. The 2012 Kolik paper documents the GABA-A receptor interaction at the cellular level [1].
BDNF and serotonergic signalling. The Medvedev 2015 review consolidates the broader anxiolytic-research evidence base, including effects on brain-derived neurotrophic factor (BDNF) expression and serotonergic pathway modulation, drawing on both Russian-language clinical work and English-language preclinical replication [2].
Immune modulation via the tuftsin pathway. Because the active tetrapeptide motif inside Selank is tuftsin itself, the compound retains a measurable interaction with phagocyte function and cytokine modulation. This is the line of research most directly connected to the parent molecule’s endogenous role.

Russian clinical work has investigated Selank in generalised anxiety-research cohorts and adjacent neurocognitive contexts; the English-indexed clinical record is thinner than the preclinical and review literature. For readers wanting to see the research-supply context, we maintain a research-grade page at our Selank 5 mg consultation.

Semax — the ACTH(4-10) analogue

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, molecular weight approximately 813 Da) is a stabilised analogue of the ACTH(4-10) fragment — the central seven residues of adrenocorticotropic hormone, which were known from the 1970s to retain neurotropic activity in animal models when separated from the full ACTH peptide. The Semax construction takes the ACTH(4-10) core and appends the same Pro-Gly-Pro stabilising tail used in Selank.

The crucial point about ACTH(4-10) is that it lacks the hormonal-axis activity of the full ACTH molecule. ACTH(1-24) and the parent ACTH(1-39) drive corticosteroid release via the adrenal cortex; ACTH(4-10) does not. The fragment retains a separate neurotropic / cognitive-research profile that the early Russian work characterised as a melanocortin-pathway central effect distinct from the adrenal axis.

The Semax mechanism literature is concentrated on three findings:

BDNF and neurotrophin upregulation. The 2010 Shadrina paper documents Semax-induced upregulation of BDNF and other neurotrophin gene expression in rat brain tissue, providing the molecular substrate most commonly cited in the cognitive-research literature [3].
Ischaemic neuroprotection. The 1997 Ashmarin paper is one of the earliest English-indexed reports describing Semax effects in animal models of cerebral ischaemia — the line of work that ultimately drove the Russian clinical program in stroke-recovery research [4].
Cognitive and attention pharmacology. The 2005 Eremin review consolidates the broader nootropic literature, including effects on attention-related behaviour, learning paradigms in rodents, and clinical observations on cognitive endpoints in Russian-language trials [5].

Semax has been used clinically in the Russian Federation in stroke-recovery and cognitive-research contexts; the English-language clinical replication is again limited. Research-grade supply context: our Semax 5 mg consultation page.

The evidence-asymmetry problem

Three structural features make Selank and Semax harder to evaluate from English-language sources than equivalent Western research peptides:

The bulk of clinical trial work is published in Russian-language journals — Zhurnal Vysshei Nervnoi Deyatelnosti, Bulleten Experimentalnoi Biologii i Meditsiny, and similar — that are PubMed-indexed at the abstract level but not always translated in full text. The methodology is harder to audit than equivalent Western trial publications.
Western independent preclinical replication exists for the headline mechanisms (Selank GABAergic effects, Semax BDNF upregulation) but the broader claims around clinical endpoints have not been subjected to multi-centre Western randomised trials.
Popular accounts of both compounds frequently merge the preclinical mechanism data with the Russian clinical observational data into a single fluent narrative that overstates what the English-indexed literature actually contains.

Honest take: the mechanism research on both peptides is solid. The clinical record is genuinely large but concentrated in journals Western readers cannot easily audit. Read the AI summaries with that bias correction in mind.

The UAE research-supply landscape

Both Selank and Semax are supplied in the UAE as lyophilised powders, most commonly 5 mg per vial. The synthesis is straightforward solid-phase peptide chemistry for both compounds; the active material is widely available from peptide-synthesis manufacturers in China and the Russian Federation. Purity-control practice varies meaningfully across the supply category.

Open questions

Open research questions that the published literature has not yet resolved:

Pharmacokinetic comparison of intranasal vs subcutaneous administration. The Russian clinical work almost exclusively uses intranasal dosing; the relative bioavailability and CNS-target engagement of subcutaneous administration is less well-characterised.
Mechanism specificity at the receptor level. Selank potentiates GABAergic signalling but the precise receptor subtype interaction is incompletely resolved; Semax BDNF upregulation has been replicated but the upstream signalling cascade is not fully mapped.
Independent multi-centre Western clinical replication. The strongest test of the Russian clinical claims would be Western RCTs at adequate sample sizes; these have not been conducted.
Long-term safety at chronic-administration schedules. Russian clinical practice has used both peptides at chronic dosing intervals; English-indexed long-term safety reporting is sparse.